About Dogwood Therapuetics
About
Dogwood Therapeutics is a development-stage biotechnology company focused on advancing novel therapeutics for pain and fatigue illness.
Dogwood’s lead product, Halneuron, is a highly selective sodium channel blocker being developed to treat moderate-to-severe chemotherapy induced neuropathic pain, cancer pain, and other pain indications. Halneuron is a small molecule that reduces pain transmission by blocking NAv 1.7, a sodium channel involved with the initiation and conduction of nerve impulses in the peripheral nervous system.
Dogwood is also pioneering the antiviral therapies IMC-1 and IMC-2 to treat diseases associated with a viral triggered abnormal immune response such as Long-COVID (“LC”) and fibromyalgia (“FM”). Overactive immune response related to activation of tissue resident herpesvirus has been postulated to be a potential root cause of chronic illnesses such as FM, irritable bowel syndrome, LC, chronic fatigue syndrome and functional somatic syndrome, all of which are characterized by a waxing and waning manifestation of disease, often triggered by events which compromise the immune system.
OUR LATEST NEWS
Read our latest press releases and sighn up for our latest email alerts